PODD Q1 2026: International Revenue Jumps 45% as Omnipod 5 Drives Global Penetration
Insulet’s Q1 saw international Omnipod revenue surge 45% as the company leverages algorithm innovation and commercial execution to expand its diabetes tech footprint. U.S. growth reflected both robust new customer starts and temporary seasonality, while disciplined pricing and improved access underpinned margin expansion. Raised full-year guidance signals confidence in durable global adoption and ongoing operating leverage.
Summary
- Global Penetration Accelerates: International Omnipod adoption outpaces expectations, led by Europe and Canada.
- Tech and Access Drive U.S. Growth: Algorithm upgrades and payer wins support U.S. leadership despite seasonal headwinds.
- Margin Leverage Builds: Manufacturing scale and pricing discipline sustain operating margin expansion.
Business Overview
Insulet (PODD) designs, manufactures, and sells tubeless insulin delivery systems for people with diabetes, primarily through its Omnipod platform, which integrates with automated insulin delivery (AID) algorithms and continuous glucose monitors (CGMs). The company generates recurring revenue from device sales and consumables across two main segments: U.S. Omnipod and International Omnipod, with the majority of revenue derived from recurring pump and pod usage.
Performance Analysis
Q1 marked a step-change in international momentum, with Omnipod revenue outside the U.S. growing 45% in constant currency and 59% as reported. European markets—especially the UK, France, and Germany—drove this acceleration, fueled by new customer starts and the ongoing transition from Dash to Omnipod 5, a next-generation AID system. Canada also contributed, following expanded reimbursement that now covers 85% of the market. The international business has now posted three consecutive quarters of over 40% growth.
U.S. Omnipod revenue grew 28%, supported by increased adoption in both Type 1 and Type 2 diabetes. New customer starts increased year-over-year but declined sequentially, a dynamic attributed to deductible resets and seasonality rather than competitive or pricing pressure. Underlying demand remains strong, with month-on-month improvement through April, and a 4% net access improvement benefiting 16 million additional lives. Adjusted operating margin expanded by 110 basis points, reflecting top-line growth, SG&A leverage, and manufacturing productivity, offset partially by transition and device correction costs.
- International Outperformance: Growth was driven primarily by volume, with price mix benefits as customers shift to Omnipod 5.
- U.S. Market Resilience: Despite Q1 seasonality, customer retention remains robust at about 90% company-wide.
- Margin Expansion: Ongoing productivity and positive pricing more than offset one-time device correction and transition costs.
Insulet’s durable recurring revenue model and expanding global footprint underpin continued operating leverage and earnings growth.
Executive Commentary
"Our first quarter performance clearly reflects the opportunity in our large and under-penetrated markets, the strength of our differentiated technology and compelling clinical outcomes, the scalability of our recurring revenue business model, and the deep expertise and commitment of our teams around the world to finding a better way for people living with diabetes."
Ashley McEvoy, President and Chief Executive Officer
"Our financial strength allows us to continue to invest for future growth while delivering margin expansion. We’re well positioned to continue driving strong earnings growth, reflecting the strength of our durable recurring revenue model, our compelling top-line trajectory, and the operating leverage we’re generating."
Flavia Peace, Chief Financial Officer
Strategic Positioning
1. Algorithm and Product Innovation
Insulet is accelerating its innovation cadence, launching three new algorithms over the next three years and integrating with new CGMs like Libre 3 Plus. The Q1 launch of a lower glucose target and improved automation in Omnipod 5 aims to enhance outcomes and ease of use, especially for Type 2 patients. The upcoming Omnipod 6, planned for 2027, and a fully closed-loop system targeting the large Type 2 market in 2028, further reinforce its tech leadership.
2. Commercial Execution and Market Access
Commercial investments are focused on sales force expansion, targeted physician engagement, and payer contracting to unlock broader access. The company doubled its U.S. peer-to-peer education program and executed 500 professional events last year, supporting strong prescriber adoption. Pharmacy channel leadership and rational pricing behavior have preserved net pricing power, with management projecting continued positive pricing over the next three years.
3. Global Manufacturing and Supply Chain Scale
Manufacturing scale is a core moat, with new capacity ramping in Malaysia, Acton, and Costa Rica to support global growth. The ability to reliably produce disposable, sophisticated electromechanical devices at consumer scale is cited as a key competitive advantage, with recent device correction handled through rapid operational response and process improvements.
4. Category Expansion and Brand Leadership
Insulet’s strategy is to expand the AID category rather than trade share, pulling new patients from multiple daily injection (MDI) therapy and underpenetrated international markets. The Omnipod brand, now the most recognized in its category, is increasingly visible in pop culture and among prescribers, supporting organic demand generation.
Key Considerations
This quarter’s results and commentary highlight Insulet’s ability to convert innovation and commercial execution into durable market share and margin gains globally. Investors should focus on the following:
- International Growth Durability: Volume-driven expansion in Europe and Canada is expected to moderate but remain robust as new launches anniversary and price mix stabilizes.
- Type 2 Diabetes Opportunity: Early innings of Type 2 adoption, with only 5% penetration and 55% CGM usage, provide a long runway as fully closed-loop systems come to market.
- Retention Dynamics: Slightly lower retention in U.S. Type 2 segment is offset by stable overall retention and improved international stickiness.
- Manufacturing and Quality Risk Management: Device correction in Q1 was absorbed operationally, with no lasting impact on new customer starts or brand reputation.
- Pricing Stability: Net pricing remains positive despite new entrants, reflecting scale advantages and payer value recognition.
Risks
Key risks include competitive entry in tubeless pumps, execution challenges in scaling manufacturing, and potential volatility in international reimbursement or regulatory environments. Management’s confidence in pricing and access is predicated on continued rational market behavior, which may not persist if competitive dynamics shift. Early Type 2 retention trends and the complexity of new product launches also warrant close monitoring.
Forward Outlook
For Q2 2026, Insulet guided to:
- Omnipod revenue growth of 21% to 23%
- Total company revenue growth of 20% to 22%, with FX providing a 100 basis point tailwind
For full-year 2026, management raised guidance to:
- Total company revenue growth of 21% to 23%
- Omnipod revenue growth of 22% to 24%
Management cited ongoing innovation launches, sales force expansion, and international market entries (including Spain and expanded Libre 3 Plus integration) as key growth drivers. Operating margin is expected to expand by 100 basis points, with EPS growth above 25% and flat free cash flow as CapEx ramps for manufacturing scale.
- International volume and price mix remain primary growth levers
- U.S. new customer starts expected to grow YoY, with stable utilization
Takeaways
Insulet’s Q1 results reinforce the sustainability of its recurring revenue model and the strategic value of global scale in diabetes technology.
- International Expansion: Europe and Canada are now major margin and volume contributors, validating the global AID adoption thesis.
- Innovation Pipeline: Successive algorithm and product launches are set to unlock new market segments and sustain category leadership.
- Execution Watchpoint: Investors should track Type 2 retention, competitive pricing, and the operational ramp of new manufacturing sites for signals on future earnings power.
Conclusion
Insulet delivered a quarter of broad-based growth and margin expansion, fueled by international outperformance and disciplined execution in the U.S. The company’s pipeline and commercial strategy provide strong visibility into continued global leadership and operating leverage, but investors should remain attentive to execution and competitive risks as the market evolves.
Industry Read-Through
The rapid international adoption of Omnipod 5 signals accelerating global acceptance of AID therapy, raising the bar for both technology and commercial execution across diabetes care. Insulet’s experience with payer access, pricing discipline, and manufacturing scale offers a blueprint for medtech peers aiming to convert innovation into durable recurring revenue. For competitors, the challenge will be matching the pace of algorithm innovation and operational reliability at scale, especially as new entrants seek to expand the tubeless pump category. The international reimbursement environment and patient onboarding support will remain critical battlegrounds as the AID market matures.